Preview: Pandemic Paradox

Hospitals are central in fight against virus, but they lost millions.

FDA Fast-Tracks Amgen Heart Drug

The U.S. Food and Drug Administration has fast-tracked Amgen Inc.’s heart failure drug omecamtiv mecarbil.

Second Sight Offering to Pay for Strategic Deal

Visual prosthetic company Second Sight Medical Products late Thursday announced a public offering of 7.5 million shares.

Amgen Beats Wall St. Expectations in First Quarter

Total revenues and net income beat analyst expectations for Thousand Oaks biotech giant Amgen Inc. during the first quarter, the company announced Thursday.

Amgen Foundation Gives $2 Million to Local Nonprofits

Amgen Foundation on Tuesday announced a $2 million contribution to more than a dozen organizations in Los Angeles and Ventura counties to help vulnerable populations impacted by COVID-19.

Arcutis Adds Legal Expertise to Board

Westlake Village-based Arcutis Biotherapeutics on Monday appointed Halley Gilbert to its board of directors. effective May 1.

Arcutis Starts Eczema Clinical Trials

At a time when many other biotech companies have curtailed clinical trials, Arcutis Therapeutics has enrolled its first patient in a Phase 1 study of hand eczema topical drug ARQ-252.

MannKind Receives $4.9 Million Loan Under CARES Act

MannKind Corp. on Wednesday announced it received a $4.9 million loan from JPMorgan Chase Bank as part of the federal CARES Act Paycheck Protection Program.

Local Hospitals See 'Leveling Off' of Coronavirus Cases

Health care systems such as Kaiser Permanente have seen a “leveling off” of COVID-19 cases, with hospital admissions to the ICU more manageable compared to two weeks ago.

Kaiser Union Reaches Coronavirus Agreement

The Coalition of Kaiser Permanente Unions said it reached an agreement with the health care giant.

Kaiser Permanente Closes Valley Facilities to Limit Virus Exposure

During the COVID-19 outbreak, Kaiser Permanente has temporarily closed select medical offices while others will limit services in an effort to control exposure to the virus.

Simulations Plus Acquires French Software Firm

Simulations Plus has acquired French medical software company Lixoft, further expanding its drug simulation capabilities and broadening its presence in Europe.

Amgen Partnership to Pursue Coronavirus Treatment

Amgen Inc. and Seattle-based Adaptive Biotechnologies on Thursday announced a strategic partnership to discover and develop a treatment for COVID-19.

Amgen Buys Out Joint Venture to Establish Japanese Subsidiary

Amgen Inc. has purchased 49 percent of shares for Amgen Astellas BioPharma, the result of a 2013 joint venture between Japanese company Astellas Pharma and the Thousand Oaks biotech giant. Financial terms of buyout were not disclosed.

Second Sight Lays Off 84 Employees Amid ‘Wind Down’ of Operations

Second Sight Medical Products Inc. on Monday announced it will lay off 84 of its 108 employees effective March 31 in response to COVID-19 challenges, the first step toward the end of the Sylmar company.